Comparison 70. Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
70.1  Participant assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
70.1.1 4 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.83, 1.21]
70.1.2 8 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.45, 0.88]
70.1.3 12 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.76 [0.49, 1.20]
70.1.4 16 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.40, 1.25]
70.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)	1		Peto Odds Ratio (Peto, Fixed, 95% CI)	Subtotals only
70.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)	1	70	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.13 [0.01, 2.14]
70.3 Physician assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
70.3.1 4 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.81, 1.16]
70.3.2 8 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.47, 0.92]
70.3.3 12 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.59 [0.40, 0.89]
70.3.4 16 weeks	1	70	Risk Ratio (M‐H, Random, 95% CI)	0.60 [0.35, 1.03]
70.4 Total adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
70.4.1 Total adverse events	1	70	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.27, 3.69]